Danirixin

Overview

Danirixin is a selective, and reversible CXCR2 antagonist, with IC 50 ?of?12.5 nM for CXCL8.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Endocrinology | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-19768
• CAS No.: 954126-98-8
• Molecular Formula: C19H21ClFN3O4S
• Molecular Weight: 441.90
• Purity: 98.19%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 5 mg/mL (11.31 mM); Clear solution
• Availability: In-stock

Source

Original product source